Literature DB >> 2993187

Effect of growth hormone on the activity of some lysosomal enzymes in neutrophilic polymorphonuclear leukocytes of hypopituitary dwarfs.

J Rovenský, J Ferencíková, M Vigas, P Lukác.   

Abstract

Elevated activities of beta-D-glucuronidase, myeloperoxidase, and lysozyme were found in polymorphonuclear leukocytes (PMNs) of both hypopituitary dwarfs and normal subjects after the administration of growth hormone (GH), as compared to the activities in PMNs from blood drawn immediately before the administration of GH. During in vitro incubation, GH was able to inhibit the release of lysosomal enzymes from resting PMNs. This inhibition may be one of the reasons for the elevated lysosomal enzyme activities observed in PMNs after the administration of GH. GH can also affect hexose monophosphate shunt (HMPS) activity and superoxide production by PMNs. The activity of HMPS is stimulated by GH in resting PMNs, while in PMNs incubated with zymosan the GH inhibits both HMPS and superoxide production.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2993187

Source DB:  PubMed          Journal:  Int J Tissue React        ISSN: 0250-0868


  3 in total

1.  Characterization of the priming effect by pituitary canine growth hormone on canine polymorphonuclear neutrophil granulocyte function.

Authors:  T K Petersen; C W Smith; A L Jensen
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

2.  Superoxide anion release from neutrophils in growth hormone deficient adults before and after replacement therapy with recombinant human growth hormone.

Authors:  N Reinisch; P Schratzberger; G Finkenstedt; C M Kähler; C J Wiedermann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996 Aug-Sep       Impact factor: 3.000

3.  Growth hormone activation of human monocytes for superoxide production but not tumor necrosis factor production, cell adherence, or action against Mycobacterium tuberculosis.

Authors:  J Warwick-Davies; D B Lowrie; P J Cole
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.